Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6 · Effective Oct 1, 2015
71 active Medicare policies list C62.00, and 9 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Aug 8, 2022
9 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C62.00 |
|---|---|---|
| Hematopoietic Cell Transplantation for Testicular Cancer | Sep 11, 2023 | Covered |
| Hyperthermia in Cancer Therapy | Feb 9, 2024 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy | Oct 3, 2023 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Feb 10, 2020
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
J15 · Effective Jul 27, 2020
JE · Effective Dec 26, 2022
JF · Effective Dec 26, 2022
JJ · Effective Feb 3, 2020
JM · Effective Feb 3, 2020
J9 · Effective Oct 1, 2015
JJ · Effective Nov 12, 2023
JM · Effective Nov 12, 2023
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Aug 6, 2026
National · Effective Aug 13, 2026
J5 · Effective Aug 6, 2026
National · Effective Aug 6, 2026
National · Effective Mar 12, 2026
National · Effective Aug 6, 2026
J5 · Effective Aug 6, 2026
National · Effective Sep 24, 2026
J5 · Effective Sep 24, 2026
National · Effective Sep 24, 2026
National · Effective Sep 24, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Jul 1, 2025
National · Effective Jul 1, 2025
National · Effective Feb 5, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 30, 2025
National · Effective Jan 1, 2026
National · Effective Jul 1, 2026
National · Effective Oct 1, 2026
| Policy | Effective | Status of C62.00 |
|---|
| Hematopoietic Stem Cell Transplantation for Germ Cell Tumors | Jan 6, 2026 | Covered |
|---|---|---|
| Human Chorionic Gonadotropin Testing | Apr 15, 2026 | Covered |
| Outpatient Alpha-Fetoprotein Testing | Apr 15, 2026 | Covered |
| Scrotal Ultrasound | Apr 15, 2026 | Covered |